Market capitalization | $6.84m |
Enterprise Value | $5.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.95 |
P/S ratio (TTM) P/S ratio | 1.19 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 52.63% |
Revenue (TTM) Revenue | $5.73m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Plus Therapeutics Inc forecast:
4 Analysts have issued a Plus Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5.73 5.73 |
53%
53%
|
|
Gross Profit | 4.92 4.92 |
70%
70%
|
|
EBITDA | -14 -14 |
2%
2%
|
EBIT (Operating Income) EBIT | -15 -15 |
3%
3%
|
Net Profit | -13 -13 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Head office | United States |
CEO | Marc Hedrick |
Employees | 20 |
Founded | 1996 |
Website | www.plustherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.